Q4 EPS Estimates for Bausch + Lomb Raised by HC Wainwright

Bausch + Lomb Corporation (NYSE:BLCO) – Analysts at HC Wainwright lifted their Q4 2025 earnings estimates for Bausch + Lomb in a research report issued to clients and investors on Friday, October 31st. HC Wainwright analyst Y. Chen now expects that the company will earn $0.31 per share for the quarter, up from their previous estimate of $0.28. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.74 per share.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.02. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the company posted $0.13 earnings per share. The business’s revenue was up 7.1% on a year-over-year basis. Bausch + Lomb has set its FY 2025 guidance at EPS.

Several other research firms also recently weighed in on BLCO. Citigroup restated a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday, October 7th. Evercore ISI increased their target price on shares of Bausch + Lomb from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. The Goldman Sachs Group began coverage on shares of Bausch + Lomb in a report on Wednesday, October 1st. They issued a “neutral” rating and a $16.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of Bausch + Lomb from $13.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Finally, Morgan Stanley increased their target price on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bausch + Lomb has a consensus rating of “Hold” and an average price target of $16.33.

Bausch + Lomb Stock Performance

BLCO opened at $14.98 on Monday. The company has a current ratio of 1.51, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76. The company’s fifty day moving average price is $15.03 and its two-hundred day moving average price is $13.64. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $20.71. The company has a market cap of $5.31 billion, a price-to-earnings ratio of -17.22, a PEG ratio of 1.63 and a beta of 0.63.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its position in Bausch + Lomb by 428.7% during the first quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after buying an additional 242,993 shares during the period. Allianz Asset Management GmbH bought a new position in Bausch + Lomb during the first quarter valued at about $4,712,000. Vident Advisory LLC bought a new position in Bausch + Lomb during the first quarter valued at about $289,000. Clearline Capital LP grew its position in Bausch + Lomb by 38.2% during the first quarter. Clearline Capital LP now owns 893,790 shares of the company’s stock valued at $12,960,000 after buying an additional 247,149 shares during the period. Finally, Trexquant Investment LP grew its position in Bausch + Lomb by 5.8% during the first quarter. Trexquant Investment LP now owns 20,255 shares of the company’s stock valued at $294,000 after buying an additional 1,108 shares during the period. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.